Is Stem Cell Therapy Legal in Thailand? The Rules Explained

In a statement dated October 31, the Medical Council of Thailand told doctors that treating any condition other than blood or eye disease with stem cells could be unlawful. A group of physicians is now suing the Council over that rule, Nation Thailand reported in December 2024. That dispute is a good place to start, because the honest answer to "is stem cell therapy legal in Thailand" has two parts: yes, for one narrow and well-established use, and for nearly everything else, only if it is done a specific way.

Reading regulatory language while you are also trying to make a decision about your own health is genuinely stressful, and you deserve a straight answer rather than a legal footnote. This article lays out what those rules actually say, based on published regulatory statements and news coverage, not on marketing claims from any clinic.

The short answer

Thailand treats blood stem cell transplantation, sometimes called hematopoietic or bone marrow transplantation, as established, standard medical care. This is the same global standard described by the International Society for Stem Cell Research: treatments in this category are "backed by convincing evidence of efficacy and safety, approved by the appropriate regulatory bodies, and widely accepted by the global medical community." For more than 50 years, doctors have used it to replace diseased blood stem cells with healthy ones, treating blood cancers, immune disorders, and some inherited metabolic diseases.

Everything else, according to the Medical Council's own October statement, is a different category. Treating conditions outside blood or eye disease with stem cells is where the Council says a doctor could be acting unlawfully, which is exactly why a group of physicians has taken the Council to court over how that line is drawn.

What "not established" means in practice

The ISSCR's patient guide describes two categories that sit below approved, standard care, and the distinction matters for anyone weighing a treatment in Bangkok.

Investigational treatments are being tested in a clinical trial. To reach that stage, a treatment should have gone through preclinical studies, review by independent experts, and approval from an ethics committee, with the trial itself using an informed consent form that spells out the risks, the alternatives, and what happens if something goes wrong.

Unproven treatments have skipped that process. The ISSCR is blunt about this: they "have not been evaluated in a rigorous, multi-step clinical trial process and thus have not been shown to be effective or safe," and are "currently being marketed and administered by unscrupulous stem cell clinics and providers around the world" in a way that "can cause physical, psychological, and/or financial harm."

Neither of those definitions is specific to Thailand. They are the international framework that any legitimate research process follows, and they are the questions worth asking a Bangkok clinic before you agree to a treatment that is not blood or eye related: is this investigational, inside a registered trial with ethics oversight, or is it being offered outside that process entirely?

What a clinic is not allowed to say

Thai advertising law does not leave this to interpretation. Section 38 of the Medical Facility Act, first passed in 1998 and amended in 2016, bans advertisements containing false, exaggerated, deceptive, or misleading statements about a facility's name or location, the services it offers, the qualifications of its staff, or the competence of its personnel.

Two real cases show what happens when a clinic crosses that line.

In August 2026, Thailand's Consumer Case Division heard a case against a beauty clinic that had advertised acne scar treatment as being run by a specialist physician, using stem cell technology it claimed could permanently remove scarring. According to Tilleke & Gibbins' account of the ruling, the court found the clinic liable for false representation and ordered it to pay the plaintiff compensation.

Separately, a legal-industry report on Lexology describes a Thai Criminal Court convicting a physician, a clinic owner, and the advertising agency they hired of criminal fraud in 2025. The case centered on Facebook and Line advertisements claiming that stem cell therapy could permanently resolve diabetes, high blood pressure, and knee degeneration. All three defendants received prison sentences and fines. It is worth reading that sentence again: a doctor, a clinic owner, and an ad agency were all held criminally responsible for one marketing campaign.

The 2026 shift: cell products as medicines

A ministerial decree reported by Nation Thailand in May 2026 changed how Thailand classifies cell-based products. Under the decree, cells that have only gone through minimal processing, such as cutting, centrifuging, cryopreserving, or simple separation, stay outside the drug framework. But products that go through "more than minimal manipulation," including culture-expanded mesenchymal stem cells, CAR-T cells, natural killer cells, dendritic cells, and induced pluripotent stem cells, are now formally classified as Advanced Therapy Medicinal Products.

That classification is not a formality. It means the product needs full Good Manufacturing Practice compliance under the PIC/S standard and formal registration with Thailand's FDA before it can be sold or administered, the same regulatory bar drug products are held to. We explain what "culture-expanded" actually means, and why it is the exact line this decree draws, in What are mesenchymal stem cells?

What real regulatory approval looks like

It helps to see what a properly approved cell product actually looks like, since it is easy to lose track of the bar once marketing language gets involved. As of this writing, the US FDA has approved exactly one mesenchymal stromal cell therapy: Ryoncil, cleared on December 18, 2024, for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months of age and older. The approval rested on a single-arm trial of 54 children, not a placebo-controlled study, in which 30 percent had a complete response and 41 percent a partial response 28 days after treatment.

That is one product, for one specific condition, in one age group, based on one named trial with its own design limits. It illustrates how narrow real regulatory approval is, anywhere in the world, for this category of cell therapy, and why a clinic's claim that something is "FDA approved" or "Thai FDA registered" needs to be checked against the actual condition you are asking about, not treated as a blanket stamp of approval.

What this is not: a ban on treatment

None of this means a patient cannot legally receive stem cell therapy in Thailand outside the blood and eye category. It means the legal and safer path runs through one of two routes: a registered clinical trial with ethics committee oversight and a proper informed consent process, or a cell product that has gone through the registration the 2026 decree now requires. A treatment offered outside both of those is the situation the Medical Council's October statement, and the advertising cases above, are actually warning against.

Questions worth asking a clinic before you book

• Is this treatment considered routine care for my specific condition in Thailand, or is it investigational?
• If it is investigational, is there a registered trial, an ethics committee, and a written informed consent form?
• Is the cell product itself registered with the Thai FDA, and for which condition?
• What is the source of the cells, and how are they processed, cut and separated only, or cultured and expanded?
• What published evidence exists for this specific use, not just for stem cells in general?

For how these regulatory realities connect to price, see How much does stem cell therapy cost? Thailand price guide 2026, since a proper written protocol and registered product should also show up in what you are being quoted.

Frequently asked questions

Is it illegal for me to receive stem cell therapy in Thailand?

Receiving treatment is not, by itself, illegal. What matters is whether the treatment is standard care, part of a properly approved research protocol with informed consent, or a product that has gone through Thai FDA registration. Ask a clinic which of these applies to what you are being offered.

What is the one stem cell treatment considered standard of care in Thailand?

Blood stem cell transplantation, also called hematopoietic or bone marrow transplantation, used for certain blood cancers, immune disorders, and inherited metabolic diseases. The Medical Council of Thailand's own October statement also names eye and corneal conditions as an established use.

Can a Thai clinic legally advertise that stem cells can permanently fix skin or aging?

No. Section 38 of the Medical Facility Act bans false, exaggerated, deceptive, or misleading claims about a facility's services or staff. A 2026 civil court case involving a beauty clinic's acne-scar claims, and a separate 2025 criminal fraud case over anti-aging ads, both turned on exactly this kind of language.

What changed with Thailand's 2026 decree on cell products?

It formally classifies cell products that have been through more than minimal processing, including culture-expanded mesenchymal stem cells, CAR-T cells, and induced pluripotent stem cells, as medicines. Producing or supplying them now requires Good Manufacturing Practice compliance and registration with the Thai FDA.

Has anyone actually been punished for misleading stem cell advertising in Thailand?

Yes. A legal-industry report describes a Thai Criminal Court convicting a physician, a clinic owner, and their advertising agency of fraud in 2025 over Facebook and Line adverts claiming stem cell therapy could permanently resolve diabetes, high blood pressure, and knee degeneration. All three received prison sentences and fines.

Does Thai FDA registration mean a treatment works?

No. Registration is about manufacturing and safety standards for the cell product itself, not proof that a specific use treats a specific condition. Ask separately what evidence exists for the condition you have, not just whether the clinic or product is registered.